Selectively stimulates pituitary somatotrophs to release GH No significant cortisol or prolactin elevation in research models Compatible with CJC-1295 for synergistic, sustained GH environment Studied for lean mass support, fat loss, improved sleep quality, and recovery 3
In April 2025 Pfizer was forced to discontinue a clinical trial with one of its experimental GLP-1 medicines to treat obesity due to potential drug induced liver injury found in one of the participants
This GPX1 polymorphism might confer a greater susceptibility to Keshan disease in carriers with low selenium nutritional status (53)
Disclaimer and Safety Information This information (and any accompanying material) is not intended to replace the attention or advice of a physician or other qualified health care professional
Specific to spinal applications, it has shown benefits in sciatic nerve repair, spinal cord injury recovery, and preliminary disc lesion models